Clinical Trial Update: Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) [Phase 2]

View source ↗

Summary

A Phase 2 trial of pembrolizumab with autologous dendritic cells for refractory colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Unresectable Colorectal Cancer

Drugs mentioned

• Autologous dendritic cells
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Metastatic Microsatellite Stable Colorectal Carcinoma, Recurrent Colorectal Carcinoma | Phase 2 | Status: WITHDRAWN